The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain ...

Dr Lotte Knudson, a scientist from Copenhagen, revolutionized research into drugs used by millions to lose weight. She has ...

A clinical trial funded by Novo Nordisk found that Ozempic (semaglutide) was linked with reduced pain among patients with ...

Researchers found a significant reduction in the risk for a first-time AD diagnosis in association with semaglutide.

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Semaglutide was linked to a significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs.

Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% ...

In this week’s Bloom Boost – health news you might have missed, Gayle Guyardo , the host of the nationally syndicated health ...

Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.